Cancer outcomes are not the same everywhere. The institutions in MediPocket's network were not selected for brand recognition — they were selected because of what their data shows.
A federal designation awarded to roughly 70 centres nationwide for research excellence and treatment quality — not given to most hospitals.
Every complex case reviewed by a panel of oncologists, radiologists, surgeons, and pathologists together — not one specialist alone.
Tumours tested at a genetic level to identify targeted therapy options that standard treatment protocols can't access.
Access to treatments still years from approval elsewhere — immunotherapy, CAR-T, and cancer vaccine protocols unavailable in most countries.
Advanced cancer care isn't only for patients who've run out of options. It's most valuable earlier — before a treatment plan is finalised.
You've received a new cancer diagnosis and want it confirmed before starting treatment
Your cancer is rare, aggressive, or has an unusual presentation
Your current treatment isn't producing the expected response
You've been told your case is complex or "difficult to treat"
Your local team has not run molecular or genomic tumour testing
You've been told there are no further treatment options
You want to know if a US tumour board would see your case differently
"Advanced cancer care" covers a specific set of services that go beyond standard chemotherapy and radiation protocols.
Tumour tissue is tested at a genetic level to identify mutations that respond to targeted drugs — turning a generic protocol into one built for your specific cancer.
Your case is reviewed jointly by oncologists, surgeons, radiologists, and pathologists in the same room — not assessed by a single specialist in isolation.
Access to surgical techniques — including robotic and minimally invasive procedures — for tumours considered inoperable or high-risk elsewhere.
Eligibility assessment against active US trials, including immunotherapy, CAR-T, and cancer vaccine protocols not yet available in most countries.
Beyond chemotherapy, surgery, and checkpoint inhibitors, a newer category of treatment is training the immune system itself to recognise and destroy cancer — using vaccines built from a patient's own tumour biology. These aren't preventive vaccines; they're personalised or targeted therapies designed for patients already living with cancer.
Built from a patient's own tumour. A biopsy sample is sequenced to identify the specific genetic mutations unique to that patient's cancer. A personalised peptide is engineered to train the immune system to recognise and target those exact mutations — making the vaccine specific to that individual's tumour, not a generic protocol.
A peptide-based vaccine that trains the immune system to recognise markers found on the blood vessels that feed tumours. Because these markers are common across roughly 98% of tumour-related blood vessels, this is an off-the-shelf option that doesn't require individual tumour sequencing.
A placenta-derived vaccine that trains the immune system to selectively identify and destroy the blood vessels supplying a tumour. As a second-generation vaccine, it has undergone clinical testing across a range of solid tumour types.
Share your diagnosis, pathology reports, scans, and treatment history. No travel required at this stage.
Our physician team reviews your records in full and identifies whether a second opinion, trial matching, or full treatment coordination is the right next step.
You're matched to the cancer centre and specialist best suited to your specific cancer type, stage, and molecular profile — not the nearest or most well-known option.
We manage specialist scheduling, pricing transparency, medical visa support, travel, accommodation, and on-ground assistance during your US visit.
After treatment, your US oncology team continues remote follow-up through MediPocket — so care continues after you return home.
These are patients who were told their treatment plan was set. A US tumour board reviewed their case. The outcome was not the same.
I had been on chemotherapy for three months when I contacted MediPocket. Within weeks I was at a US cancer centre with a completely different treatment plan — one specific to the mutations in my tumour. I wish I had made the call sooner.
My oncologist told me there was nothing more to be done. MediPocket found a clinical trial at MD Anderson I qualified for. That conversation changed my life.
The tumour board at MSK reviewed my case differently than my local team had. They found a surgical option I was told wasn't possible.
I had been on chemotherapy for three months when I contacted MediPocket. Within weeks I was at a US cancer centre with a completely different treatment plan — one specific to the mutations in my tumour. I wish I had made the call sooner.
My oncologist told me there was nothing more to be done. MediPocket found a clinical trial at MD Anderson I qualified for. That conversation changed my life.
The tumour board at MSK reviewed my case differently than my local team had. They found a surgical option I was told wasn't possible.
No commitment. Our physician team reviews every case personally and responds within 24 hours.
If your treatment plan was set without a multidisciplinary tumour board review, molecular testing, or clinical trial assessment — there may be more to your case than you've been told. The first review costs nothing.